14
Views
9
CrossRef citations to date
0
Altmetric
Research Article

Contrasting cardiac regional responses of A-type and B-type natriuretic peptide to experimental chronic heart failure

Pages 299-310 | Published online: 08 Jul 2009

REFERENCES

  • de Bold AJ, Borenstein HB, Veress AT, Sonnenberg H. A rapid and potent natriuretic response to intravenous injection of atrial myo-cardial extract in rats. Life Sci 1981; 28: 89–94.
  • Flynn TG, de Bold ML, de Bold AJ. The amino acid sequence of an atrial peptide with potent diuretic and natriuretic properties. Biochem Bio-phys Res Commun 1983; 117: 859–65.
  • Kangawa K, Matsuo H. Purification and complete amino acid sequence of alpha-human atrial natriuretic polypeptide (alpha-hANP). Biochem Biophys Res Commun 1984; 118: 131–9.
  • Saito Y, Nakao K, Itoh H, Yamada T, Mukoyama M, Arai H, Hosoda K, Shirakami G, Suga S, Minamino N, et al. Brain natriuretic peptide is a novel cardiac hormone. Biochem Biophys Res Commun 1989; 158: 360–8.
  • Sudoh T, Kangawa K, Minamino N, Matsuo H. A new natriuretic peptide in porcine brain. Nature 1988; 332: 78–81.
  • Sudoh T, Maekawa K, Kojima M, Minamino N, Kangawa K, Matsuo H. Cloning and sequence analysis of cDNA encoding a precursor for human brain natriuretic peptide. Biochem Biophys Res Commun 1989; 159: 1427–34.
  • Chang MS, Lowe DG, Lewis M, Hellmiss R, Chen E, Goeddel DV. Differential activation by atrial and brain natriuretic peptides of two different receptor guanylate cyclases. Nature 1989; 341: 68–72.
  • Sonnenberg H, Cupples WA, de Bold AJ, Veress AT. Intrarenal localization of the natriuretic effect of cardiac atrial extract. Can J Physiol Pharmacol 1982; 60: 1149–52.
  • Deth RC, Wong K, Fukozawa S, Rocco R, Smart JL, Lynch CJ, Awad R. Inhibition of rat aortacontractile respons by natriuresis-inducing extract of rat atrium. Fed Proc 1982; 41: 983.
  • Goetz KL. Physiology and pathophysiology of the atrial peptides. Am J Physiol 1988; 254: E1—E15.
  • Needleman P, Greenwald JE. Atriopeptin: a cardiac hormone intimately involved in fluid, electrolyte, and blood-pressure homeostasis. N Engl J Med 1986; 314: 828–34.
  • Itoh H, Nakao K, Yamada T, Shirakami G, Kangawa K, Minamino N, Matsuo H, Imura H. Antidipsogenic action of a novel peptide, "brain natriuretic peptide", in rats. Eur J Pharmacol 1988; 150: 193–6.
  • Yoshimura M, Yasue H, Morita E, Sakaino N, Jougasaki M, Kurose M, Mukoyama M, Saito Y, Nakao K, Imura H. Hemodynamic, renal, and hormonal responses to brain natriuretic peptide infusion in patients with congestive heart failure. Circulation 1991; 84: 1581–8.
  • Maack T, Suzuki M, Almeida FA, Nussenzveig D, Scarborough RM, McEnroe GA, Lewicki JA. Physiological role of silent receptors of atrial natriuretic factor. Science 1987; 238: 675–8.
  • Kenny AJ, Bourne A, Ingram J. Hydrolysis of human and pig brain natriuretic peptides, urodi-latin, C-type natriuretic peptide and some C-receptor ligands by endopeptidase- 24.11. Biochem J 1993; 291: 83–8.
  • Ogawa Y, Nakao K. Brain natriuretic peptide as a cardiac hormone in cardiovascular disorders. In: Laragh JH, Brenner BM, editors. Hypertension: pathophysiology, diagnosis, and management. 2nd ed. New York: Raven Press, 1995: 833–40
  • Burnett JC Jr, Kao PC, Hu DC, Heser DW, Heublein D, Granger JP, Opgenorth TJ, Reeder GS. Atrial natriuretic peptide elevation in con-gestive heart failure in the human. Science 1986; 231: 1145–7.
  • Mukoyama M, Nakao K, Hosoda K, Suga S, Saito Y, Ogawa Y, Shirakami G, Jougasaki M, Obata K, Yasue H, et al. Brain natriuretic peptide as a novel cardiac hormone in humans. Evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide. J Clin Invest 1991; 87: 1402— 12.
  • Omland T, Aakvaag A, Vik-Mo H. Plasma cardiac natriuretic peptide determination as a screening test for the detection of patients with mild left ventricular impairment. Heart 1996; 76: 232–7.
  • Yoshimura M, Yasue H, Okumura K, Ogawa H, Jougasaki M, Mukoyama M, Nakao K, Imura H. Different secretion patterns of atrial natriuretic peptide and brain natriuretic peptide in patients with congestive heart failure. Circulation 1993; 87: 464 — 9.
  • Morita E, Yasue H, Yoshimura M, Ogawa H, Jougasaki M, Matsumura T, Mukoyama M, Nakao K. Increased plasma levels of brain natriuretic peptide in patients with acute myocar-dial infarction. Circulation 1993; 88: 82–91.
  • Haug C, Metzele A, Kochs M, Hombach V, Grunert A. Plasma brain natriuretic peptide and atrial natriuretic peptide concentrations correlate with left ventricular end-diastolic pressure. Clin Cardiol 1993; 16: 553–7.
  • Mathisen P, Hall C, Simonsen S. Comparative study of atrial peptides ANF (1-98) and ANF (99-126) as diagnostic markers of atrial distension in patients with cardiac disease. Scand J Clin Lab Invest 1993; 53: 41–9.
  • Nakamura M, Kawata Y, Yoshida H, Arakawa N, Koeda T, Ichikawa T, Funakoshi T, Hiramori K. Relationship between plasma atrial and brain natriuretic peptide concentration and hemo-dynamic parameters during percutaneous trans-venous mitral valvulotomy in patients with mitral stenosis. Am Heart J 1992; 124: 1283–8.
  • Richards AM, Nicholls MG, Yandle TG, Frampton C, Espiner EA, Turner JG, Buttimore RC, Lainchbury JG, Elliott JM, Ikram H, Crozier IG, Smyth DW. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: new neurohormonal predictors of left ventricular func-tion and prognosis after myocardial infarction. Circulation 1998; 97: 1921–9.
  • McDonagh TA, Robb SD, Murdoch DR, Morton JJ, Ford I, Morrison CE, Tunstall-Pedoe H, McMurray JJ, Dargie HJ. Biochemical detection of left-ventricular systolic dysfunction [see com-ments]. Lancet 1998; 351: 9–13.
  • Ogawa Y, Nakao K, Mukoyama M, Hosoda K, Shirakami G, Arai H, Saito Y, Suga S, Jougasaki M, Imura H. Natriuretic peptides as cardiac hormones in normotensive and spontaneously hypertensive rats. The ventricle is a major site of synthesis and secretion of brain natriuretic pep-tide. Circ Res 1991; 69: 491— 500.
  • Tamura N, Ogawa Y, Itoh H, Arai H, Suga S, Nakagawa 0, Komatsu Y, Kishimoto I, Takaya K, Yoshimasa T, et al. Molecular cloning of hamster brain and atrial natriuretic peptide cDNAs. Cardiomyopathic hamsters are useful models for brain and atrial natriuretic peptides. J Clin Invest 1994; 94: 1059–68.
  • Spinale FG, Hendrick DA, Crawford FA, Smith AC, Hamada Y, Carabello BA. Chronic supra-ventricular tachycardia causes ventricular dysfunc-tion and subendocardial injury in swine. Am J Physiol 1990; 259: H218–29.
  • Klinge R, Hystad ME, Kjekshus J, Kalberg BE, Djoseland 0, Aakvaag A, Hall C. An experi-mental study of cardiac natriuretic peptides as markers of development of congestive heart fail-ure. Scand J Clin Lab Invest 1998; 58: 683–92.
  • Sambrook J, Fritsch EF, Maniatis T. Molecular cloning: a laboratory manual. 2nd ed. New York: Cold Spring Harbor Laboratory Press, 1989
  • Klinge R, Djoseland 0, Karlberg BE, Hall C. Cardiac secretion of atrial and brain natriuretic peptides in acute ischemic heart failure in pigs: effect of angiotensin II receptor antagonism. Clin Physiol 1997; 17: 389–400.
  • Luchner A, Stevens TL, Borgeson DD, Redfield M, Wei CM, Porter JG, Burnett Jr JC. Differ-ential atrial and ventricular expression of myo-cardial BNP during evolution of heart failure. Am J Physiol 1998; 274: H1684–9.
  • Moe GW, Grima EA, Wong NL, Howard RJ, Armstrong PW. Plasma and cardiac tissue atrial and brain natriuretic peptides in experimental heart failure. J Am Coll Cardiol 1996; 27: 720–7.
  • Takahashi T, Allen PD, lzumo S. Expression of A-, B-, and C-type natriuretic peptide genes in failing and developing human ventricles. Correla-tion with expression of the Ca(2+)-ATPase gene. Circ Res 1992; 71: 9–17.
  • Hosoda K, Nakao K, Mukoyama M, Saito Y, Jougasaki M, Shirakami G, Suga S, Ogawa Y, Yasue H, Imura H. Expression of brain natriuretic peptide gene in human heart. Production in the ventricle. Hypertension 1991; 17: 1152–5.
  • Adachi S, Ito H, Ohta Y, Tanaka M, Ishiyama S, Nagata M, Toyozaki T, Hirata Y, Marumo F, Hiroe M. Distribution of mRNAs for natriuretic peptides in RV hypertrophy after pulmonary arterial banding. Am J Physiol 1995; 268: H162–9.
  • Mukoyama M, Nakao K, Saito Y, Ogawa Y, Hosoda K, Suga S, Shirakami G, Jougasaki M, Imura H. Human brain natriuretic peptide, a novel cardiac hormone [letter]. Lancet 1990; 335: 801–2.
  • Colucci WS. Molecular and cellular mechanisms of myocardial failure. Am J Cardiol 1997; 80: 15L–25L.
  • Stein BC, Levin RI. Natriuretic peptides: physiol-ogy, therapeutic potential, and risk stratification in ischemic heart disease. Am Heart J 1998; 135: 914— 23.
  • Sutton SJ. Left ventricular remodelling after acute myocardial infarction. 1st ed. London, UK: Science Press, 1996
  • de Bold AJ. Tissue fractionation studies on the relationship between an atrial natriuretic factor and specific atrial granules. Can J Physiol Pharmacol 1982; 60: 324–30.
  • Nakao K, Saito Y, Itoh H, Ogawa Y, Nakagawa 0, Harada M, Masuda I, Yoshimasa T. Roles of natriuretic peptides in heart failure. J Card Fail 1996; 2: S129–33.
  • Benjamin BA, Metzler CH, Peterson TV. Chronic atrial appendectomy alters sodium excretion in conscious monkeys. Am J Physiol 1988; 254: R699–705.
  • Suga S, Nakao K, Hosoda K, Mukoyama M, Ogawa Y, Shirakami G, Arai H, Saito Y, Kambayashi Y, Inouye K, et al. Receptor selectivity of natriuretic peptide family, atrial natriuretic peptide, brain natriuretic peptide, and C-type natriuretic peptide. Endocrinology 1992; 130: 229–39.
  • Nagase M, Katafuchi T, Hirose S, Fujita T. Tissue distribution and localization of natriuretic peptide receptor subtypes in stroke-prone spontaneously hypertensive rats. J Hypertens 1997; 15: 1235–43.
  • Hall C, Rouleau JL, Moye L, de Champlain J, Bichet D, Klein M, Sussex B, Packer M, Rouleau J, Arnold MO, et al. N-terminal proatrial natriuretic factor. An independent predictor of long-term prognosis after myocardial infarction [see comments]. Circulation 1994; 89: 1934–42.
  • Lerman A, Gibbons RJ, Rodeheffer RJ, Bailey KR, McKinley LJ, Heublein DM, Burnett Jr JC. Circulating N-terminal atrial natriuretic peptide as a marker for symptomless left-ventricular dysfunc-tion [see comments]. Lancet 1993; 341: 1105–9.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.